What this is
- How it works
- How it works isn't classified yet
- Tested for
- Tinnitus
- Main trialPhase 2
- “This study will consist of two parts. Double blind Part A will assess the safety, tolerability, and pharmacokinetics of 7 days of dosing in healthy adults, while open label Part B will evaluate the safety, tolerability, and efficacy of a 2-week treatment course in adults with tinnitus.”In the company’s words, NCT07777549 on ClinicalTrials.gov
Other drugs for Tinnitus
- EbselenSound Pharmaceuticals, Incorporated · Phase 3
- Isosorbide oral solutionLunan Better Pharmaceutical Co., LTD. · Phase 2/3
- PalirodenCilcare SAS · Phase 1/2
Coming up1
- Aug 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Aug 2027 | A Study of the Safety and Efficacy of TRTL-913 in Healthy Volunteers (Part A) and in Adults With Tinnitus (Part B) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026